Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.

[1]  Martin C. Müller,et al.  Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells , 2014 .

[2]  C. Gambacorti-Passerini,et al.  The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis , 2014 .

[3]  J. Cayuela,et al.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Mustjoki,et al.  Immunology and Immunotherapy of Chronic Myeloid Leukemia , 2014, Current Hematologic Malignancy Reports.

[5]  U. Olsson‐Strömberg,et al.  Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells , 2014 .

[6]  T. Yoshimoto,et al.  Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib , 2013, Cancer science.

[7]  L. Costa.  Defects in DBA: more than meets the eye , 2013 .

[8]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[9]  C. Carcassi,et al.  Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. , 2013, Experimental hematology.

[10]  P. Parham,et al.  Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution , 2013, Nature Reviews Immunology.

[11]  D. Greco,et al.  Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. , 2012, Experimental hematology.

[12]  D. Marin,et al.  KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib , 2012, Leukemia.

[13]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[14]  K. Campbell,et al.  自然杀伤细胞与癌症——杀伤细胞免疫球蛋白样受体（KIR）的调控 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[15]  P. Gourraud,et al.  Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. , 2009, Tissue antigens.

[16]  J. Goldman,et al.  Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? , 2006, Leukemia & lymphoma.

[17]  K. Hsu,et al.  The killer cell immunoglobulin‐like receptor (KIR) genomic region: gene‐order, haplotypes and allelic polymorphism , 2002, Immunological reviews.